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Introduction: Recent studies showed that phenylalanine (Phe) plasma concentrations may decrease in some
patients with hyperphenylalaninemia (HPA) due to phenylalanine hydroxylase (PAH) deficiency, after the
administration of tetrahydrobiopterin (BH4).
Objective: To determine responsiveness to a single dose of BH4 administered according to an innovative
protocol using a combined Phe and BH4 loading test in Brazilian phenylketonuria (PKU) patients.
Methods: Patient age should be ≥4 years, and median Phe plasma concentration ≤600 μmol/L when following
dietary restrictions. Participants received a simple Phe loading test using 100 mg/kg L-Phe (Test 1) and a com-
bined Phe+BH4 loading test using 100 mg/kg L-Phe and 20mg/kg/BH4 (Test 2). Blood samples were collected
at baseline and 3, 11 and 27 h after Phe ingestion (T0, T1, T2 and T3). Responsiveness was defined as: criterion
A: plasma Phe reduction of ≥30% at T1 and T2 for Tests 1 and 2; criterion B: plasma Phe reduction of ≥30% at
T1 and T3 for Tests 1 and 2; and criterion C: at least 30% difference of the areas under the Phe curve for Tests 1
and 2.
Results: Eighteen patients (median age 12 yrs; 8 classical PKU; 10 mild PKU) participated in the study. Six
patients (2 classical PKU; 4 mild PKU) were classified as responsive according to at least one of the criteria.
Responsiveness was concordant when criteria A+B we compared with criterion C (kappa=0.557; p=0.017).
Of the patients whose genotype was available (n=16), six had data about BH4-responsiveness genotypes
described in the literature, which were in agreement with our findings.
Conclusion: The comparison of simple Phe loading and combined Phe+BH4 loading seems to be an optimal
method to evaluate responsiveness to BH4 in patients with good metabolic control.
© 2011 Elsevier Inc. All rights reserved.1. Introduction
Phenylketonuria (PKU) or hyperphenylalaninemia due to phenyl-
alanine hydroxylase (PAH) deficiency is an inborn error of amino acid
metabolism characterized by the persistent increase of phenylalanine
(Phe) plasma concentration. PAH converts Phe into tyrosine (Tyr), in
the presence of its cofactor tetrahydrobiopterin (BH4) [1].a, Hospital de Clínicas de Porto
gre, RS, Brazil.
artz).
rights reserved.The standard PKU treatment is based on a Phe-restricted diet and
ingestion of a Phe-free amino acid-rich metabolic formula that supplies
the daily protein requirements of a patient [1,2]. Because of the toxic
effects of high Phe levels, this condition, if left untreated, may lead to
neurological impairment, mental retardation and behavioral disorders
[3,4].
The necessary dietary restriction and the associated difficulty to
adhere to the treatment [4–6], have motivated the search for new
PKU management strategies [7]. Since the publication of the study
by Kure et al. [8], who described the first case of patients with PKU
whose Phe levels decreased after BH4 administration, several studies
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tion, which has already been approved by the FDA and the EMEA.
Patients are usually evaluated to check their responsiveness and, in
case results suggest that they are responsive, that is, that Phe levels
will decrease after BH4 administration, BH4 supplementation is initiat-
ed. Studies, however, have used different protocols to evaluate re-
sponsiveness: BH4 doses are different and may range from 10 to
20 mg/kg/day in a single dose or distributed along the day; test
evaluation times range from some hours to weeks or even months;
the cut-off point of Phe variation defined to determine responsiveness
also varies, and the criterion most frequently adopted is a decrease of
30% in Phe levels 24 h after BH4 administration. In addition, different
diets are used during tests: normal diets, Phe-restricted diet, or even
a Phe-loading diet using, for example, powder milk or L-Phe [7,9–22].
This study describes responsiveness to a single dose of BH4 in a
sample of Brazilian patients with PKU and good metabolic control.
For that purpose, an innovative protocol with a single Phe plus a
combined Phe and BH4 loading tests was used.
2. Material and methods
This study included patients with PKU seen in the Outpatient
Metabolic Disorder Treatment Clinic of the Medical Genetics Service
of Hospital de Clínicas de Porto Alegre (ATDM-SGM/HCPA), Porto
Alegre, Brazil. At the time this study was conducted, 68 patients
with different phenotypes were followed up in the ATDM-SGM/HCPA
and 64 of them underwent dietary treatment.
This study was approved by the Ethics in Research Committee of
HCPA, and all patients or their guardians signed a written informed
consent term.
2.1. Patients
Patients included in the study should be aged ≥4 years and
should be under dietary treatment; median Phe plasma levels
should be ≤600 μmol/L in the 12 months before the start of the
study. The Phe cut-off point adopted ensured that patients with
the mild form of the disease, good metabolic control, or both
were also included in the test. A previous trial conducted by our
study team [23] adopted a different protocol and different inclu-
sion criteria to evaluate responsiveness to BH4, and most patients
had the classical form of the disease and inadequate metabolic
control, as their Phe plasma levels had to be ≥360 μmol/L in all
measurements during the previous 12 months.
Exclusion criteria were: pregnancy, clinical signs suggestive of
liver disease; use of levodopa; allergy to any component of BH4;median
Phe levelN600 μmol/L in the measurements made in the 12 months
before inclusion in the study; irregular follow-up in the ATDM-SGM/
HCPA in the same 12 months; and probable non-compliance with
study procedures according to evaluations made by the authors.
PKU types were defined according to Nalin et al. [6], and the
patients were classified as having classical PKU or mild PKU.
2.2. Single Phe and combined Phe+BH4 loading tests
The patients were asked to come to two visits in HCPA and to stay
under evaluation for 27 h each time; the two visits were made at a
one-week interval.
2.2.1. Simple Phe loading (Test 1)
In the first week, after overnight fasting, blood was collected to
measure Phe and Tyr plasma concentrations (T0). After that, patients
ingested 100 mg/kg of L-Phe and resumed their usual diet (Phe-
restricted diet and supplementation with Phe-free metabolic formula).
Blood for Phe and Tyr was then collected at 3 (T1), 11 (T2) and 27 h
(T3) after Phe loading.2.2.2. Combined Phe and BH4 loading (Test 2)
In the second week, evaluation was conducted using the protocol
described by Blau et al. [24], with a modification, as Phe and Tyr levels
were not analyzed 7 h after Phe loading. The initial phases of Test 2
(collection at T0, Phe loading, food ingestion, and blood collection
at T1) were similar to those described for Test 1. In addition, immedi-
ately after collection at T1 bloods sample, a single dose of 20 mg/kg
BH4 (sapropterin dihydrochloride, KUVAN®, Merck Serono) was
administered orally and samples were collected at 8 h (T2) and 24 h
(T3) after BH4 ingestion. Time points T0 and T1 of Tests 1 and 2
were, therefore, equivalent to each other, whereas T2 and T3 were
differed in that BH4 administration was included in Test 2.
L-Phe and BH4 were dissolved in orange juice before administration.
Patients were told to fast for at least 1 h before all blood collections.
Phe and Tyr plasma concentrations were measured using tandem
mass spectrometry (MS/MS) in the Laboratory of Inborn Errors of
Metabolism of SGM/HCPA, as described by Rashed et al. [25]. All mea-
surements were made in duplicate, and the mean of the two measure-
ments was calculated. In Test 2 samples, the levels of BH4 (total
biopterins) were also measured, according to the method of Opladen
et al. [26].
2.3. Responsiveness to BH4
Patients were defined as responsive to BH4 if they met at least one
of the criteria listed below:
Criterion A: this criterion used Phe values at T1 [3 h after Phe loading
in Tests 1 (1T1) and 2 (2T1)] and at T2 [11 h after Phe loading in
Tests 1 (1T2) and 2 (2T2) and 8 h after BH4 administration in Test
2]. The following equation was used for calculations: [((2T2−
2T1)/2T1)×100]−[((1T2−1T1)/1T1)×100].
Individuals were responsive if the values found corresponded to a
reduction of ≥30% in Phe levels in Test 2.
Criterion B: this criterion used Phe values at T1 and T3 [27 h after
Phe loading in Tests 1 (1T3) and 2 (2T3) and 24 h after BH4 ad-
ministration in Test 2]. The following equation was used for calcu-
lations: [((2T3−2T1)/2T1)×100]− [((1T3−1T1)/1T1)×100].
Individuals were responsive if the values found corresponded to a
reduction of ≥30% in Phe levels in Test 2.
Criterion C: this criterion used the percentage difference of the
value found for the area under the Phe curve in Tests 1 (AUC1)
and 2 (AUC2). The following equation was used for calculations:
[((AUC2−AUC1)/AUC1)×100]. Individuals were responsive if
the difference was ≥30%, as long as the Test 1 area was greater
than the Test 2 area.
To compare the classification of responsiveness, four additional
criteria were used, as described below:
Criterion D: only the Phe values at T1 and T2 of Test 2 were used. The
following equation was used for calculations: [((2T2−2T1)/2T1)×
100]. Individuals were responsive if the values found corresponded
to a reduction of ≥30% in Phe levels in time point 2.
Criterion E: only the Phe values at T1 and 3 of Test 2 were used. The
following equation was used for calculations: [((2T3−2T1)/2T1)×
100]. Individuals were responsive if the values found corresponded
to a reduction of ≥30% in Phe levels in time point 3.
Criterion F: this criterion was used by the authors in a previ-
ous study [23] to evaluate the responsiveness of 5 patients
also included in this study, and was defined as a reduction
of ≥30% in Phe levels 8 h after simple BH4 loading (single-
dose of BH4 at 20 mg/kg, without a concomitant load of Phe or
L-Phe).
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study [23] to evaluate the responsiveness of 5 patients also included
in this study, and was defined as a reduction of ≥30% in Phe levels
24 h after simple BH4 loading.
2.4. Dietary intake of Phe
Phe intake was evaluated using food recalls on the day before and
on the first day of Tests 1 and 2, which totaled, therefore, two recalls
for each Test. Dietary Phe intake was calculated using the nutrition-
support software NutriBase (NB7), Clinical Edition. All patients
received instructions to keep the same dietary Phe prescription that
they followed before the beginning of the study.2.5. Genotype
Genotypes of patients 1 to 17 (Table 1) were established previously
and retrieved from their medical charts. Patient 18 was the only patient
who had not been genotyped at the time of the study.2.6. Statistical analysis
The Statistical Package for Social Sciences 18.0 (SPSS® Inc., Chicago,
IL) was used for statistical analysis. Data were described using absolute
and relative frequencies. The Stata program was used to calculate the
area under the Phe curve. Continuous variables were expressed as
mean±standard deviation or median and interquartile range. The
Shapiro–Wilk test was used to analyze variable distribution.
The Student t test was used to compare Phe intake between the
different food recalls, the area under the Phe curve, and the difference
in Phe levels between the collection time points for responsive pa-
tients versus non-responsive patients. Phe plasma concentrations
and Phe:Tyr ratios were analyzed using Generalized Estimating
Equations and Bonferroni correction. The comparison between BH4
responsiveness criteria was made using kappa statistics.
The level of significance was set at 5%.Table 1
Genotype, PKU phenotype for each patient and comparison of responsiveness in this study
Patient Type of
PKU
Genotype Responsiveness to BH
(our study)
Allele 1 Allele 2
1 Classical p.I65T p.R408W R
2 Classical p.V388M p.V388M R
3 Classical p.I65T p.R176X NR
4 Classical p.R252W p.R261Q NR
5 Classical p.165T p.I65T NR
6 Mild p.E390G p.R408Q R
7 Classical p.R261X p.R176X NR
8 Mild p.R408W c.165delT NR
9 Mild p.R408W c.165delT NR
10 Mild p.E390G p.A104D R
11 Mild p.R408W p.L348V NR
12 Mild p.R408W p.L348V NR
13 Mild p.A300S p.L311P R
14 Classical p.R408W p.R408W NR
15 Mild p.R261Q p.V388M R
16 Mild p.L249F p.V388M NR
17 Classical c.165delT ? NR
18 Mild ? ? NR
PKU: phenylketonuria; Nd: not described; R: Responsive; NR: non-responsive; Siblings: 8 a
a To be classified as responsive, patient had to obtain a positive result according to at lea
b Data retrieved from BIOPKUdb http://www.bh4.org/BH4DatabasesBioHPA-PAH.asp.
c Loading protocol used in other PKU patients with the same genotype (amount of BH4 p
d Patients with a Phe reduction of 20 to 30% after BH4 loading.3. Results
Eighteen patients (11 girls and 7 boys) from 16 nonrelated families
were included in the study. Parental consanguinity was found in 1/16
(6.25%) family. Median patient age was 12 (interquartile range: 10–
16.5) years; minimum age was 6, and maximum, 31 years.
Mean Phe levels in Tests 1 and 2 at T0 were 255±138 and 333±
173 μmol/L (n=18; p=0.342), and at T1, 730±221 and 790±310
(n=18; p=1.0). In both Tests 1 and 2 there were significant increases
in Phe levels between T0 and T1 (pb0.01). There were no statistically
significant differences in Phe:Tyr ratios when the same time points
were compared between Tests 1 and 2.
BH4 plasma levels in Test 2 increased after L-Phe administration
(T1) and BH4 loading (T2) (data not reported).3.1. Response to BH4
Six patients (33.3%) were responsive, four according to criterion A,
three according to criterion B, and four according to criterion C
(Table 2). The comparison of BH4-responsiveness according to crite-
rion used is shown in Table 3. In the calculation of the Kappa Index,
the data reported by Giugliani et al. [23] were not included because
of the small sample size (5/18 patients included in this study).
Kappa was 0.557 when criteria A+B were compared with criterion
C (p=0.017). For the other criteria, Kappa values indicated a weak
agreement.
For responsive patients, mean Phe level variations between time
points T1 and T2 and between time points T1 and T3 were different
only in Test 2 (p=0.002 and 0.011, respectively), that difference
was not found for non-responsive patients (Table 2). The analysis
of area under the curve (AUC) revealed a statistically significant
difference between Tests 1 and 2 mean values for responsive pa-
tients (pb0.01), but not for non-responsive patients (p=0.242)
(Table 2).
Fig. 1 shows the Phe plasma concentration values found in this
study according to collection time point in Tests 1 and 2 for a BH4-
responsive patient (Fig. 1A) and a non-responsive patient (Fig. 1B).with findings in the literature.
4
a Responsiveness to BH4
(number of patients included)b
Protocol used in the literaturec
R (2) BH4(10 mg) — 24 h
R (1) — Slow R (1)d BH4(20 mg) — 24 h
Nd Nd
Nd Nd









NR(13) Slow R (1)d BH4(20 mg) — 24 h (13)/Other (1)
R (1) BH4(10 mg) — 8 h
NR (1) BH4(20 mg) — 24 h
– –
– –
nd 9; 11 and 12.
st one of the criteria used (criteria A, B and C).
er kg of current weight; time used for responsiveness criterion).
Table 2
BH4 responsiveness: Phe values and corresponding areas under the curve (n=18 patients).






Phe (μmol/L) Phe (μmol/L) AUC1 AUC2
T1 T2 T3 T1 T2 T3
Responsive
1 852 1032 949 1010 823 816 373.1 289.8 −39.6 −30.6 −22.3
2 1193 1314 849 939 895 639 435.2 297.2 −14.8 −3.1 −31.7
6 588 474 136 570 144 74,8 133.8 27.9 −55.3 −10 −79.1
10 522 372 113 612 127 58,4 103.1 19.3 −50.5 −12.1 −81.3
13 744 602 550 748 516 189 207.1 145.2 −11.9 −48.6 −29.9
15 657 822 589 819 498 355 281.6 153.1 −64.3 −46.3 −45.6
μ±sd 759±242 769±358 531±349 783±175⁎ 500±324⁎ 355±312⁎ 255.6±132.0⁎⁎ 155.4±120.9⁎⁎ −39.4±21.7 −25.1±19.5 −48.3±25.8
Non-responsive
3 1095 750 706 991 946 808 253.2 327.3 27 17 29.3
4 702 555 462 496 553 390 185.9 186.6 32.4 12.8 0.4
5 517 427 530 652 661 494 161.1 223.4 18.7 −26.7 38.6
7 816 775 617 634 696 542 263.5 239.5 14.8 9.9 −9.1
8 367 425 390 699 726 715 152.9 263.0 −11.9 −3.9 72.0
9 544 626 486 742 736 730 216.4 265.8 −15.8 9 22.8
11 836 655 613 608 513 418 225.7 172.6 6 −4.5 −23.5
12 991 925 717 1095 855 660 311.9 280.7 −15.2 −12 −10.0
14 711 562 296 587 421 197 171.3 123.6 −7.3 −8 −27.8
16 789 640 446 714 637 422 206.6 206.4 8.1 2.5 −0.1
17 790 810 799 1810 1787 1398 293.2 608.1 −3.8 −23.9 107.4
18 422 350 227 489 304 208 111.7 93.1 −20.8 −11.2 −16.7
μ±sd 715±220 625±172 524±174 793±367 736±375 582±323 212.8±60.0 249.2±131.0 2.6±17.8 −3.2±14 15.3±41.1
Phe: phenylalanine; Test 1: simple Phe loading; Test 2: combined Phe+BH4 loading; Siblings: 8 and 9; 11 and 12.
Criterion A: [((2T2−2T1)/2T1)×100]− [((1T2−1T1)/1T1)×100].
Criterion B: [((2T3−2T1)/2T1)×100]− [((1T3−1T1)/1T1)×100].
Criterion C: [((AAC2−AAC1)/AAC1)×100].
To be classified as responsive, patient had to obtain a positive result according to at least one of the criteria used (criteria A, B and C).
T1 — time point 1: Phe level 3 h after Phe loading; T2 — time point 2: Phe level 11 h after Phe loading and 8 h after BH4 loading (Test 2); T3 — time point 3: Phe level 27 h after Phe
loading and 24 h after BH4 loading (Test 2); AUC1: Area under the curve in Test 1; AUC2: Area under the curve in Test 2.
⁎ Phe variation between T2 and T1 and between T3 and T1 was statistically significant (p=0.002 and 0.011).
⁎⁎ Statistically significant difference (pb0.01).
Table 3















1 R R NR NR NR NR R
2 NR NR R NR R – –
3 NR NR NR NR NR R R
4 NR NR NR NR NR – –
5 NR NR NR NR NR – –
6 R NR R R R – –
7 NR NR NR NR NR – –
8 NR NR NR NR NR – –
9 NR NR NR NR NR – –
10 R NR R R R – –
11 NR NR NR NR R R R
12 NR NR NR NR R NR NR
13 NR R NR R R – –
14 NR NR NR NR R – –
15 R R R R R – –
16 NR NR NR NR R NR NR
17 NR NR NR NR NR – –
18 NR NR NR R R – –
R=responsive; NR=non-responsive.
The criteria are defined in the Material and methods section of this study.
Siblings: 8 and 9; 11 and 12.
a Data reported by Giugliani et al. [23].
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Data about the genotype, severity of PKU and BH4-responsiveness
are shown in Table 1.
3.3. Dietary intake
The patients ingested in average 705.56±356.77 and 608.89±
405.51 mg (mean±SD) of Phe per day, according to dietary recalls
1 and 2 of Test 1 (p=0.446), and 672.78±406.17 and 572.78±
329.47 mg (mean±SD) of Phe per day according to dietary recalls 1
and 2 of Test 2 (p=0.281). There were no statistically significant dif-
ferences in Phe intake between Tests 1 (657.2±379.6 mg Phe/day)
and 2 (622.7±368 mg Phe/day) (p=0.564).
4. Discussion
In this study, patients with PKU that might potentially benefit
from the use of BH4 were identified by comparing their Phe levels
after a simple Phe loading test and after a combined Phe+BH4 load-
ing test. Although no consensus has been reached in the literature
about the most adequate method to identify these individuals, Phe
plasma levels should be elevated at the time of BH4 administration
to induce an increase in PAH activity and, consequently, to potentiate
the effect of BH4 [27]. This recommendation adds complexity to the
investigation of BH4 responsiveness in patients with good adherence
to dietary treatment. The increase of Phe levels is often achieved by
increasing the ingestion of dietary Phe [8,9,20,22,28–30], which may
raise ethical and psychological issues. A single Phe dose using L-Phe
may also be administered, with the advantage that the patient's diet
does not have to be changed [19,31–33]; however, Phe levels afterthis type of loading tend to spontaneously decrease in 24 h even
when BH4 is not been administered [20,32]. Therefore, BH4 respon-
siveness would have to be confirmed by comparing Phe plasma levels
after the Phe+BH4 loading test and after the simple Phe loading test.
We have found in the literature only two studies performing the sim-
ple Phe loading test and the combined Phe+BH4 loading test in the
Fig. 1. (A) Phe variation in a patient classified as responsive to BH4 according to collec-
tion time points. (B) Phe variation in a patient classified as non-responsive to BH4
according to collection time points.
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patients with Phe level at diagnosis below 360 μmol/L, but classified
their responsiveness only according to the combined Phe+BH4 test;
and the one conducted by Ponzone et al. [32], which included seven
patients with different forms of PKU, but did not establish clear
criteria for the classification of responsiveness. The analysis of Phe
curves in both studies suggests that Phe plasma levels reach similar
values at the end of the simple Phe and combined Phe+BH4 loading
tests; although, Phe levels seem to decrease faster when BH4 is used.
The protocol to evaluate responsiveness in this study is innovative
for two reasons: (1) it included the use of a simple Phe and a combined
Phe+BH4 loading test for 18 patients with PKU and good metabolic
control; (2) it defined BH4 responsiveness parameters based on the
comparison of results of these two tests. According to the strategy
adopted in this study, 33.3% (6/18) of the patients were classified as
responsive, which is in agreement with data in the literature [17–
19,23,30,34]. Of the responsive patients, two had the classical PKU
(n=2/8; 25.5%) and four, the mild PKU (n=4/10; 40%), which
confirmed that responsiveness is greater among individuals with
milder forms of PKU. Moreover, of the 16 patients for whom genotypes
were available, six had data about BH4-responsiveness genotypes
described in the literature.
Therewas also an important discordance between the seven criteria
used to compare the definition of responsiveness. In the group of 18
individuals, only one was responsive and six were non-responsive
according to all criteria. If criteria 4 and 5, which consider the results
of combined Phe+BH4 loading only, had not been used, a greater num-
ber of patients would have concordant results for non-responsiveness
(n=10). The use of criteria 4 and 5 independently seems to lead to a
greater number of diagnoses of patients responsive to BH4; this may
be explained by the fact that these criteria do not take into consider-
ation that Phe may be excreted spontaneously and not due to BH4
action.Although the protocol here described has some limitations, e.g.
the need for patients to attend the treatment center twice (two con-
secutive weeks) and to undergo a higher number of blood collections,
the superiority of this protocol when compared with others already
described in the literature can only be assessed if comparative studies
are carried out. This underscores the need for determining the sensi-
tivity, specificity, as well as positive and negative predictive values of
these tests, especially if we take into consideration that, as our
findings clearly show, patients diagnosed as BH4-responsive accord-
ing to one given protocol may not be diagnosed as such in another
protocol. In this sense, one of the future goals of the authors is to
test simple BH4 loading in all patients included in the present study.
4.1. Comments on dietary ingestion and Phe levels during the Tests
Dietary Phe ingestion did not change in the two recalls in the same
Test, and there was also no variation in the comparison of total Phe
amount ingested in Test 1 and in Test 2, which suggests that the fall in
Phe levels in responsive individualswas secondary to BH4 administration.
The variation of Phe plasma concentrations along the study
revealed an elevation at time point T1 in comparison with time
point T0, that is, 3 h after Phe loading, which demonstrates, therefore,
that L-Phe was absorbed by the patient. The collection point 3 h after
Phe loading was used because it has been described in the literature
as the point at which Phe plasma levels peak predominantly [24].
However, in 9 patients in this study, the highest Phe plasma concen-
tration values occurred at least, in one of the Tests, 11 h after Phe
loading, which has also been reported by other studies [19,20].
Phe plasma concentrations at time points 0 and 1 in the two Tests
did not differ from each other, which emphasizes their comparability.
4.2. Conclusions
BH4 has emerged as a new treatment for patients with mostly
milder forms of PKU and may substantially improve their quality of
life. Numerous positive findings, including increases in Phe tolerance,
have been reported in association with the use of this medication.
However, no consensus has been reached about the best method
and criteria to define responsiveness to BH4. The validation of
methods and criteria for this purpose is fundamental to optimize
the treatment with BH4 also in terms of cost and effectiveness. Our
data suggest that, in responsive individuals, Phe levels decrease faster
after Phe+BH4 loading than after simple Phe loading, and confirm
that the comparison between simple Phe and combined Phe+BH4
loading is valid to evaluate responsiveness. Moreover, because of
the wide range of variation of responsiveness classification for each
patient, more than one criterion should be used to establish a defini-
tion, and these criteria should take into consideration the comparison
between the values obtained in single Phe and combined Phe+BH4
loading tests.
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